Business / Finance

RSS

LCA-Vision's revenues decrease $25.5M to 9.8% in first quarter 2014

LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus® brand, today announced financial and operating results for the three months ended March 31, 2014.

30 Apr 2014

Alkermes reports financial results for first quarter of 2014

Alkermes plc today reported financial results for the first quarter of 2014. "During the quarter, we continued to generate positive cash flow, reflecting the strength of our commercial business and enabling us to invest in our advancing late-stage pipeline and prepare for the launch of aripiprazole lauroxil," commented James Frates, Chief Financial Officer of Alkermes.

30 Apr 2014

Denmark and China announce food safety partnership

On 25 April, a new memorandum of understanding between DTU and CFSA was signed by Martin Bends-e, DTU Senior Vice President and Dean, at a ceremony in Beijing witnessed by HRH Queen Margrethe II and Prince Henrik of Denmark.

30 Apr 2014

ICON Q1 2014 net revenue increases 10% to $349.6 million

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2014.

30 Apr 2014

InDevR, Applied Microarrays partner to offer complete system solution for multiplexed assays

InDevR Inc., a Boulder-based biotechnology company, and Applied Microarrays, Inc., a Tempe-based contract microarray manufacturer have partnered to deliver a complete system solution for multiplexed assays. The platform includes custom protein and DNA arrays, reagents and protocols, a fluorescent scanner for slides or plates (Vidia) and a colorimetric scanner for lower throughput applications (ampliPHOX).

30 Apr 2014

Cerus, Nipro partner to develop key component of INTERCEPT red cell disposable set

Cerus Corporation announced today that it has entered into a collaboration agreement with the Nipro Corporation's pharmaceutical division to develop technology to support commercial implementation of the INTERCEPT System for Red Blood Cells (RBCs).

29 Apr 2014

HCA Holdings Q1 2014 revenues up 4.6%

HCA Holdings, Inc. today announced financial and operating results for the first quarter ended March 31, 2014.

29 Apr 2014

Endo enters into definitive agreement to acquire Grupo Farmaceutico Somar

Endo International plc today announced it has entered into a definitive agreement under which Endo will acquire Grupo Farmaceutico Somar, a leading privately-owned specialty pharmaceuticals company based in Mexico City, Mexico, for cash consideration. Endo expects the transaction to be immediately accretive to adjusted earnings per share.

29 Apr 2014

YourEncore announces partnership extension with Roche to provide expert solutions

YourEncore, a leading provider of expert solutions to the life sciences, consumer health and nutrition industries, today announced a partnership extension with Roche to provide expert solutions and services to support enhancing productivity and strengthening regulatory compliance.

29 Apr 2014

DJOFL first quarter 2014 net sales increase 1.3% to $282.7 million

DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its public reporting subsidiary, DJO Finance LLC, for the first quarter ended March 29, 2014.

29 Apr 2014

Doximity closes $54 million Series C fundraising round

Doximity, the professional network for doctors, today announced closing a $54 million Series C fundraising round co-led by DFJ and funds and accounts managed by T. Rowe Price Associates, Inc. Funds and accounts managed by Morgan Stanley Investment Management also participated in the round as new investors.

29 Apr 2014

Waters reports sales of $431 million for first quarter 2014

Waters Corporation reported today first quarter 2014 sales of $431 million, essentially flat versus sales of $430 million in the first quarter of 2013. In the quarter, the effect of foreign currency translation was neutral to sales growth.

29 Apr 2014

Armetheon reaches agreement with FDA on SPA for final pivotal trial of tecarfarin

Armetheon, Inc., today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the final pivotal trial of tecarfarin.

29 Apr 2014

Bristol-Myers Squibb completes acquisition of iPierian

Bristol-Myers Squibb Company and iPierian, Inc. announced today that Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of Tau protein in the human brain.

29 Apr 2014

Magellan Health Services reports net revenue of $966.5 million for first quarter 2014

Magellan Health Services, Inc. today reported financial results for the first quarter 2014, as summarized below. For the quarter ended March 31, 2014, the company reported net revenue of $966.5 million, segment profit of $76.5 million, and net income of $25.7 million, or $0.92 earnings per share (EPS).

29 Apr 2014

Columbia Laboratories' total revenues increase 15% to $7.2 million in first quarter 2014

Columbia Laboratories, Inc. today announced financial results for the three-month period ended March 31, 2014.

29 Apr 2014

Emilia Group completes acquisition of Pharma Pac's strategic assets

Emilia Group is pleased to announce the recent acquisition of strategic assets of Pharma Pac LLC, an OTC private brand and contract manufacturer, located in DeKalb, MS. The new entity is named Emilia Resources LLC and will operate as a manufacturing company of pharmaceutical and cosmetic products that will combine with Emilia Personal Care's strength in sales, marketing, supply chain and customer service.

28 Apr 2014

Truven Health Analytics announces acquisition of Fortel Analytics' healthcare fraud technology

Truven Health Analytics, a leading provider of healthcare analytics and data solutions and services, today announced the acquisition of Fortel Analytics' healthcare fraud technology. The acquisition gives Truven Health exclusive access to a breakthrough suite of predictive solutions, analysis methods and analytic technology designed to quickly identify suspicious patterns in healthcare insurance claims data before claims are ever paid.

28 Apr 2014

Forest Laboratories enters into definitive agreement to acquire Furiex

Forest Laboratories, Inc. nd Furiex Pharmaceuticals, Inc. today announced that Forest has entered into a definitive agreement to acquire Furiex, a drug development collaboration company, for $95 per share, or approximately $1.1 billion in cash, and up to $30 per share (approximately $360 million in aggregate) in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

28 Apr 2014

Voluntis closes €20.75 million ($29 million) Series D financing round

Voluntis, a company pioneering therapeutic companion software, today announced the completion of its Series D financing round. With a total of €20.75 million ($29 million), this fund raising is one of the largest rounds of investment in the m-health sector this year.

28 Apr 2014